Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/19
End: 05/31/22
Due: 05/31/23
Phase: N/A
Priority: Normal
Start: 05/31/19
End: 05/31/22
Due: 05/31/23
Phase: N/A
Priority: Normal
Start: 05/31/19
End: 05/31/22
Due: 05/31/23
Phase: N/A
Priority: Normal
Start: 05/31/19
End: 05/31/22
Due: 05/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | NCT03940820 | Asclepius Technology Company Group (Suzhou) Co., Ltd. | user2@example.com | None | 2019-05-31 | 2022-05-31 | 2023-05-31 | - | - | 2025-07-14 |
| Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | NCT03940833 | Asclepius Technology Company Group (Suzhou) Co., Ltd. | user2@example.com | None | 2019-05-31 | 2022-05-31 | 2023-05-31 | - | - | 2025-07-14 |
| Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor | NCT03931720 | Asclepius Technology Company Group (Suzhou) Co., Ltd. | user2@example.com | None | 2019-05-31 | 2022-05-31 | 2023-05-31 | - | - | 2025-07-14 |
| Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer | NCT03941457 | Asclepius Technology Company Group (Suzhou) Co., Ltd. | user2@example.com | None | 2019-05-31 | 2022-05-31 | 2023-05-31 | - | - | 2025-07-14 |